Compositions and methods for the prevention and treatment of cardiovascular diseases

Abstract

Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.

What is claimed is: 
     
         1 . A therapeutic composition comprising an electro-activated solution with a stable negative oxidation-reduction potential in a range between −50 mV and −500 mV, a conductivity between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6. 
     
     
         2 . The composition of  claim 1 , wherein the electro-activated solution comprises:
 0.5-10% Magnesium sulfate hexahydrate;   5.0-20% Ascorbic Acid;   0.2-2.0% Niacinamide;   0.005-2% Pyridoxin HCl;   0.01-2.0% Calcium D Pantothenate;   0.1-1.0% Thiamin HCl;   0.01-0.1% Riboflavin; and   0.001-0.1% Cyanocobalamin.   
     
     
         3 . The composition of  claim 2  further comprising one or more of 0.5-10% Sodium Bicarbonate, 0.05-10% sodium lactate, or 1.0-3.0% 2-di-ethylaminoethanol. 
     
     
         4 . The composition of  claim 1 , wherein the electro-activated solution comprises sodium bicarbonate, sodium chloride, and magnesium sulfate or magnesium chloride. 
     
     
         5 . The composition of  claim 4 , wherein the sodium bicarbonate is at 0.5-1.0 g/1, the sodium chloride is at 8.0-10.0 g/l, and the magnesium sulfate or magnesium chloride is at 4.5-7.5 g/1. 
     
     
         6 . A method for treating or preventing a dysfunctional cardiovascular condition in a subject in need thereof comprising parenterally administering to the subject a stable composition comprising a therapeutically effective amount of an electro-activated solution, wherein the electro-activated solution has an oxidation-reduction potential in the range between −50 mV and −500 mV, a conductivity in the range between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6. 
     
     
         7 . The method of  claim 6 , wherein the composition comprises:
 0.5-10% Magnesium sulfate hexahydrate;   5.0-20% Ascorbic Acid;   0.2-2.0% Niacinamide;   0.005-2% Pyridoxin HCl;   0.01-2.0% Calcium D Pantothenate;   0.1-1.0% Thiamin HCl;   0.01-0.1% Riboflavin; and   0.001-0.1% Cyanocobalamin.   
     
     
         8 . The method of  claim 7 , wherein the composition further comprises one or more of 0.5-10% Sodium Bicarbonate, 0.05-10% sodium lactate, and 1.0-3.0% 2-di-ethylaminoethanol. 
     
     
         9 . The method of  claim 6 , wherein the composition comprises sodium bicarbonate, sodium chloride, and magnesium sulfate or magnesium chloride. 
     
     
         10 . The method of  claim 9 , wherein the sodium bicarbonate is at 0.5-1.0 g/l, the sodium chloride is at 8.0-10.0 g/1, and the magnesium sulfate or magnesium chloride is at 4.5-7.5 g/1. 
     
     
         11 . A method of preparing a therapeutic composition with a stable negative oxidation-reduction potential in a range between −50 mV and −900 mV, a conductivity between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6, the method comprising:
 mixing a first electroactivated solution with a second electroactivated solution, the first electroactivated solution having a stable negative oxidation-reduction potential and the second electroactivated solution having a stable positive oxication-reduction potential. 
 
     
     
         12 . The method of  claim 11 , wherein the first electroactivated solution is prepared by
 adding ascorbic acid or sodium ascorbate to a concentration of 83.6-95.5 g/L and 90.0-100.0 g/L, respectively, to an electro-activated water, and   stirring until dissolved the ascorbic acid or sodium ascorbate are dissolved.   
     
     
         13 . The method of  claim 12  further comprising adding 2-diethylaminoaceto xylidide to the electro-activated water prior to adding the ascorbic acid or sodium ascorbate. 
     
     
         14 . The method of  claim 13  further comprising adding one or more selected from salts, vitamins, and cyanocobalamin. 
     
     
         15 . The method of  claim 14 , wherein the first electroactivated solution produced has an oxidation-reduction potential in the range between −500 mV and −900 mV for a period of at least 12 months and a pH in the range between 3.2 and 4.5, and one liter of the first electroactivated solution comprises: 83.6-95.5 g/L Ascorbic acid; 57.1-64.7 g/L Magnesium Sulphate hexahydrate; 28.5-32.5 g/L 2-diethylaminoaceto xylidide; 9.4-10.6 g/L Niacinamide; 9.4-10.6 g/L Pyridoxin HCl; 0.18-0.29 g/L Riboflavin-5-phosphate sodium; 5.75-6.5 g/L Thiamin HCl; 0.17-0.2 g/L Cyanocobalamin crystalline; and 997.50 ml Electrochemically activated water. 
     
     
         16 . The method of  claim 11 , wherein the second electroactivated solution is prepared by
 adding sodium bicarbonate, sodium chloride, a salt selected from magnesium sulfate and magnesium chloride and optionally calcium to an electro-activated water until complete dissolution, wherein the solution has a positive oxidation-reduction potential in a range between +500 mV and +900 mV and a pH between 6.5 and 7.8.   
     
     
         17 . The method of  claim 16 , wherein one liter of the second electroactivated solution comprises 82.4-93.2 g/L Sodium Bicarbonate USP, 19.1-21.8 g/L Magnesium Sulphate hexahydrate; and 998.5 ml Electrochemically activated water. 
     
     
         18 . The method of  claim 11 , wherein the first electroactivated solution has an oxidation-reduction potential in the range between −500 mV and −900 mV for a period of at least 12 months and a pH in the range between 3.2 and 4.5, and one liter of the first electroactivated solution comprises: 83.6-95.5 g/L Ascorbic acid; 57.1-64.7 g/L Magnesium Sulphate hexahydrate; 28.5-32.5 g/L 2-diethylaminoaceto xylidide; 9.4-10.6 g/L Niacinamide; 9.4-10.6 g/L Pyridoxin HCl; 0.18-0.29 g/L Riboflavin-5-phosphate sodium; 5.75-6.5 g/L Thiamin HCl; 0.17-0.2 g/L Cyanocobalamin crystalline; and 997.50 ml Electrochemically activated water;
 the second electroactivated solution has an oxidation-reduction potential in the range between +500 mV and +900 mV for a period of at least 12 months and a pH in the range between 6.5 and 7.8, and one liter of the second electroactivated solution comprises 82.4-93.2 g/L Sodium Bicarbonate USP, 19.1-21.8 g/L Magnesium Sulphate hexahydrate; and 998.5 ml Electrochemically activated water; 
 and the step of mixing comprises mixing equal volumes of the first electroactivated solution and the second electroactivated solution. 
 
     
     
         19 . A therapeutic composition comprising the product of the method of  claim 11 . 
     
     
         20 . A therapeutic composition comprising the product of the method of  claim 13 .